FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017231335> ?p ?o ?g. }

• W2017231335 endingPage "1050" @default.
• W2017231335 startingPage "1042" @default.
• W2017231335 abstract "Enoxaparin reduces ischemic events more effectively than unfractionated heparin (UFH) in patients treated conservatively for non-ST-segment elevation acute coronary syndrome. The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding.This article compares the outcomes of the 4687 SYNERGY patients (47%) undergoing percutaneous coronary intervention, who were randomized to receive enoxaparin or UFH. Antithrombotic therapy was administered prerandomization in 78%. Crossover (usually in the catheterization laboratory) to the alternative antithrombotic occurred in 14.6% of enoxaparin patients and 2.9% of UFH-treated patients (P < .0001). Stenting was performed in 86.3%. Abrupt vessel closure occurred in 1.3% of enoxaparin patients and 1.7% of UFH-treated patients (P = .318). The rates of death/MI were similar at 30 days (13.1% with enoxaparin vs 14.2% with UFH, P = .289). GUSTO severe bleeding occurred with similar frequency in both groups (1.5% vs 1.6%, P = .688). TIMI major bleeding was more common with enoxaparin (3.7% vs 2.5% with UFH, P = .028). Transfusions were more frequent with enoxaparin than with UFH (6.8% vs 5.4%, P = .047). TIMI major bleeding increased with crossover from enoxaparin to UFH (from 3.7% to 7.8%) and from UFH to enoxaparin (from 2.5% to 8.6%). Statistical adjustment to model reasons for crossover did not affect the overall safety and efficacy outcomes.In high-risk patients undergoing early percutaneous coronary intervention for acute coronary syndrome, enoxaparin avoids the need for monitoring and achieves similar effectiveness to UFH but is associated with more bleeding." @default.
• W2017231335 created "2016-06-24" @default.
• W2017231335 creator A5002193815 @default.
• W2017231335 creator A5013409359 @default.
• W2017231335 creator A5018064879 @default.
• W2017231335 creator A5024398972 @default.
• W2017231335 creator A5039283108 @default.
• W2017231335 creator A5039432822 @default.
• W2017231335 creator A5039754301 @default.
• W2017231335 creator A5047661952 @default.
• W2017231335 creator A5052994249 @default.
• W2017231335 creator A5060254903 @default.
• W2017231335 creator A5060370891 @default.
• W2017231335 creator A5060829829 @default.
• W2017231335 creator A5062843291 @default.
• W2017231335 creator A5085360484 @default.
• W2017231335 creator A5087016151 @default.
• W2017231335 date "2006-12-01" @default.
• W2017231335 modified "2023-10-07" @default.
• W2017231335 title "Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial" @default.
• W2017231335 cites W1983126671 @default.
• W2017231335 cites W1991588150 @default.
• W2017231335 cites W2021206861 @default.
• W2017231335 cites W2041914551 @default.
• W2017231335 cites W2085869089 @default.
• W2017231335 cites W2091795351 @default.
• W2017231335 cites W2092213174 @default.
• W2017231335 cites W2120569650 @default.
• W2017231335 cites W2136473335 @default.
• W2017231335 cites W2141192690 @default.
• W2017231335 cites W2149599987 @default.
• W2017231335 cites W2158336299 @default.
• W2017231335 cites W2316460201 @default.
• W2017231335 cites W2344256737 @default.
• W2017231335 cites W2748139581 @default.
• W2017231335 doi "https://doi.org/10.1016/j.ahj.2006.08.002" @default.
• W2017231335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17161049" @default.
• W2017231335 hasPublicationYear "2006" @default.
• W2017231335 type Work @default.
• W2017231335 sameAs 2017231335 @default.
• W2017231335 citedByCount "85" @default.
• W2017231335 countsByYear W20172313352012 @default.
• W2017231335 countsByYear W20172313352013 @default.
• W2017231335 countsByYear W20172313352014 @default.
• W2017231335 countsByYear W20172313352016 @default.
• W2017231335 countsByYear W20172313352017 @default.
• W2017231335 countsByYear W20172313352018 @default.
• W2017231335 countsByYear W20172313352019 @default.
• W2017231335 countsByYear W20172313352021 @default.
• W2017231335 countsByYear W20172313352022 @default.
• W2017231335 countsByYear W20172313352023 @default.
• W2017231335 crossrefType "journal-article" @default.
• W2017231335 hasAuthorship W2017231335A5002193815 @default.
• W2017231335 hasAuthorship W2017231335A5013409359 @default.
• W2017231335 hasAuthorship W2017231335A5018064879 @default.
• W2017231335 hasAuthorship W2017231335A5024398972 @default.
• W2017231335 hasAuthorship W2017231335A5039283108 @default.
• W2017231335 hasAuthorship W2017231335A5039432822 @default.
• W2017231335 hasAuthorship W2017231335A5039754301 @default.
• W2017231335 hasAuthorship W2017231335A5047661952 @default.
• W2017231335 hasAuthorship W2017231335A5052994249 @default.
• W2017231335 hasAuthorship W2017231335A5060254903 @default.
• W2017231335 hasAuthorship W2017231335A5060370891 @default.
• W2017231335 hasAuthorship W2017231335A5060829829 @default.
• W2017231335 hasAuthorship W2017231335A5062843291 @default.
• W2017231335 hasAuthorship W2017231335A5085360484 @default.
• W2017231335 hasAuthorship W2017231335A5087016151 @default.
• W2017231335 hasConcept C126322002 @default.
• W2017231335 hasConcept C141071460 @default.
• W2017231335 hasConcept C164705383 @default.
• W2017231335 hasConcept C2776884760 @default.
• W2017231335 hasConcept C2777015399 @default.
• W2017231335 hasConcept C2777557582 @default.
• W2017231335 hasConcept C2777698277 @default.
• W2017231335 hasConcept C2777995511 @default.
• W2017231335 hasConcept C2778825682 @default.
• W2017231335 hasConcept C2780400711 @default.
• W2017231335 hasConcept C500558357 @default.
• W2017231335 hasConcept C71924100 @default.
• W2017231335 hasConceptScore W2017231335C126322002 @default.
• W2017231335 hasConceptScore W2017231335C141071460 @default.
• W2017231335 hasConceptScore W2017231335C164705383 @default.
• W2017231335 hasConceptScore W2017231335C2776884760 @default.
• W2017231335 hasConceptScore W2017231335C2777015399 @default.
• W2017231335 hasConceptScore W2017231335C2777557582 @default.
• W2017231335 hasConceptScore W2017231335C2777698277 @default.
• W2017231335 hasConceptScore W2017231335C2777995511 @default.
• W2017231335 hasConceptScore W2017231335C2778825682 @default.
• W2017231335 hasConceptScore W2017231335C2780400711 @default.
• W2017231335 hasConceptScore W2017231335C500558357 @default.
• W2017231335 hasConceptScore W2017231335C71924100 @default.
• W2017231335 hasIssue "6" @default.
• W2017231335 hasLocation W20172313351 @default.
• W2017231335 hasLocation W20172313352 @default.
• W2017231335 hasOpenAccess W2017231335 @default.
• W2017231335 hasPrimaryLocation W20172313351 @default.
• W2017231335 hasRelatedWork W2035403045 @default.
• W2017231335 hasRelatedWork W2039623794 @default.

• next